GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immix Biopharma IMMX · USD

Health Care · US listing · 🇺🇸 United States

Compare

8.57

+6.33%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Immix Biopharma

From its filings with the US Securities and Exchange Commission

SEC filings

Immix Biopharma is based in Los Angeles, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IMMX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $29.4m. At that date it held total assets of $104.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Dec 2021
Employees
21
Head office
11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Ilya RachmanChairman of the Board, Chief Executive Officer, since 2012$1.3m
  • Dr. Vladimir TorchilinScientific Co-Founder
  • Mr. Gabriel MorrisChief Financial Officer, Director, since 2021$1.3m
  • Dr. Graham RossActing Chief Medical Officer, Head - Clinical Development$88,593
  • Ms. Helen AdamsLead Independent Director$124,226
  • Dr. Nancy ChangDirector
  • Ms. Jane BuchanIndependent Director$112,226
  • Ms. Yekaterina ChudnovskyIndependent Director$93,726
  • Mr. Jason HsuIndependent Director$93,976
  • Dr. Magda MarquetIndependent Director$105,726
  • Mr. Carey NgIndependent Director$99,226

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in the Health Care sector with a focus on biopharmaceutical development.
  • Lead asset IMX-110 is in Phase Ib/IIa clinical trials for solid tumors in the US and Australia.
  • TME Normalization Technology enables drug candidates to target the tumor micro-environment effectively.

Weaknesses

  • Company employs only 21 employees, which may limit operational capacity.
  • The source description states 9 full-time employees, conflicting with the provided employee count.
  • Company has not yet commercialized any products, relying on clinical trials for development.

Opportunities

  • IMX-111 and IMX-120 are in development for colorectal cancer and inflammatory bowel disease.
  • TME Normalization Technology could differentiate the company in the biotechnology sector.
  • Potential for expansion into additional therapeutic areas beyond cancer and inflammatory diseases.

Threats

  • Clinical trial failures could delay or halt development of IMX-110 and other drug candidates.
  • Competition in the biotechnology sector may impact market positioning and funding.
  • Reliance on a single lead asset (IMX-110) increases risk if trials are unsuccessful.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.